Semaglutide fails in Alzheimer’s trials: systemic gaps in metabolic-cognitive health integration revealed by phase 3 studies
Original framing: “[Articles] Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials” — The Lancet
The trickster here is the pharmaceutical industry itself, masquerading as a healer while profiting from chronicity. Like Hermes, it delivers messages of hope (new drugs) but delivers only delay (trial failures) and profit. The trials’ focus on a single drug in a complex disorder is a classic trickster’s sleight-of-hand—diverting attention from root causes (e.g., corporate food systems) to a symptom (Alzheimer’s) that requires systemic change. The absurdity lies in the fact that a drug failing in 2026 was touted as a breakthrough in 2020, revealing the cyclical nature of biomedical hype.
The semaglutide trials’ failure is not an anomaly but a symptom of a biomedical paradigm that isolates symptoms from their systemic roots—metabolic dysfunction, environmental toxins, and social inequity.
This paradigm, shaped by pharmaceutical interests and Western reductionism, has repeatedly failed Alzheimer’s patients, from the amyloid hypothesis to today’s metabolic drugs, while marginalized communities bear the brunt of its consequences. Cross-cultural wisdom—from Navajo *Hózhǫ́* to Okinawan *moai*—offers a blueprint for prevention through diet, community, and land-based therapies, yet these models are sidelined in favor of patentable drugs. The trickster’s role is clear: the industry’s promise of a 'cure' distracts from the urgent need for systemic change, where food systems, environmental regulation, and community care converge. The path forward requires dismantling the pharmaceutical-first model, centering marginalized voices, and embracing a holistic, metabolic-cognitive health ecosystem—one where Alzheimer’s is treated as a preventable, not inevitable, condition.